LLY vs NVS
Eli Lilly and Company Common Stock vs Novartis AG Common Stock. Scores ACCE, valorisation, rentabilité et croissance côte à côte.
$LLY vs $NVS: Growth Dominance vs Defensive Quality
$LLY is the clear winner for growth-oriented exposure. Revenue is up 47.7% year-over-year, earnings grew 26.2%, and the stock has returned 60.5% over the past year. Its ACCE Growth score of 92 and Momentum score of 90 reflect a business firing on all cylinders, with a 33.5% net margin confirming that the top-line surge is translating into real profit. The analyst consensus target of $1,315.04 implies further upside from the current $1,174.61.
The catch is valuation. At a forward P/E of 32.4 and a 6-model fair value of $452.30, the market is pricing in a great deal of future execution. The Value score of 17 says it plainly.
$NVS is the opposite trade. A forward P/E of 17.3, a 3.1% dividend yield, and a FCF yield of 6.0% make it genuinely cheap. Its Quality score of 96 is the highest of the two, and ROE of 30.3% is far stronger than $LLY's 1.0%. The problem is growth: revenue up just 0.8% and earnings down 17.0% year-over-year leave little near-term catalyst.
Winner: $LLY, for investors comfortable paying a premium for proven, accelerating growth. $NVS suits those prioritising income and capital preservation.